Agilent Technologies Inc (A)vsInsight Molecular Diagnostics Inc. (IMDX)
A
Agilent Technologies Inc
$112.98
-1.07%
HEALTHCARE · Cap: $31.96B
IMDX
Insight Molecular Diagnostics Inc.
$4.14
+3.50%
HEALTHCARE · Cap: $122.19M
Smart Verdict
WallStSmart Research — data-driven comparison
Agilent Technologies Inc generates 160395% more annual revenue ($7.07B vs $4.40M). A leads profitability with a 18.3% profit margin vs 0.0%. A earns a higher WallStSmart Score of 61/100 (C+).
A
Buy61
out of 100
Grade: C+
IMDX
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-318.5%
Fair Value
$30.80
Current Price
$112.98
$82.18 premium
Intrinsic value data unavailable for IMDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 20 in profit
Strong operational efficiency at 22.9%
Revenue surging 126.1% year-over-year
Areas to Watch
Grey zone — moderate risk
Weak financial health signals
Earnings declined 3.6%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -236.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : A
The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : IMDX
The strongest argument for IMDX centers on Revenue Growth. Revenue growth of 126.1% demonstrates continued momentum.
Bear Case : A
The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.
Bear Case : IMDX
The primary concerns for IMDX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
A profiles as a mature stock while IMDX is a hypergrowth play — different risk/reward profiles.
IMDX carries more volatility with a beta of 1.35 — expect wider price swings.
IMDX is growing revenue faster at 126.1% — sustainability is the question.
A generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
A scores higher overall (61/100 vs 27/100), backed by strong 18.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agilent Technologies Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
Insight Molecular Diagnostics Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?